Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × piperine × Clear all
NCT04731844 2026-05-12

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

University of Rochester

Phase 2 Completed
30 enrolled 13 charts
GenitourinaryPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡